Press Releases
Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550
Oxis International Enters into a Sponsored Research Agreement with the University of Minnesota
OXIS Biotech Scientific Advisory Board Member to Address Cancer Immunotherapy Conference in China
Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma
Oxis Biotech Announces Enrollment of 2 New Patients in FDA Clinical Trial of Promising Cancer Drug OXS-1550
